TGRX-678

· Shenzhen TargetRx Co., Ltd.

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for TGRX-678, covering 2025-02-21 to 2026-03-24. Get the full timeline:

Most recent: Clinical Trial Update: TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients [Phase 3]